The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.


Updates from The Motley Fool

Latest updates on Amarin from Fool.com.  The Fool has written over 300 articles on Amarin.
7 Top Stocks to Buy in March

The market may have rebounded from its February lows, but now might be the perfect time to buy sh...



Stock Performance

View Interactive AMRN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Amarin.
Current Price: $3.25
Prev Close: $3.23
Open: $3.24
Bid: $3.23
Ask: $3.24
Day's Range: $3.21 - $3.28
52wk Range: $1.40 - $3.65
Volume: 347,255
Avg Vol 1,717,267
Market Cap: $884M
P/E (ttm): -7.88
EPS (ttm): ($0.41)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Amarin.
CAPS Rating 3 out of 5
 
299 Outperform
27 Underperform
CAPS All Stars
 
30 Outperform
6 Underperform

How do you think Amarin will perform against the market?



You pick for Amarin is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Joseph S. (Joe) Zakrzewski, CEO

24% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Amarin.

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers